Why I’d buy these 2 overlooked FTSE 100 stocks today

Don’t overlook these two FTSE 100 (INDEXFTSE:UKX) stocks or you could be missing out, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s all too easy to stick to the same big familiar names when hunting down FTSE 100 stocks for your portfolio. You know the usual suspects, BP, Lloyds Banking Group, GlaxoSmithKline… all good companies, of course, but it’s worth looking a little further as well.

Here are a couple that I have to confess I haven’t paid much attention to myself. So have I missed out on a brace of hidden gems?


International sales, marketing and support services group DCC (LSE: DCC) has seen its stock more than double in the past five years, turning it into a £7bn business. However, the share price trajectory has flattened out lately, with the share price now trading at roughly similar levels to three years ago.

The group has been a strong and steady grower, with earnings per share rising by double digits for each of the last five years although, again, there are signs of a slowdown. EPS growth is expected to slow to 4% both this year and next.

This looks like a growth stock rather than play, as the yield is just 2.1%, although nicely covered 2.5 times by earnings. The group’s four divisions – LPG, Retail & Oil, Technology and Healthcare – look set to continue growing quite nicely, according to management, which said in July’s Q1 statement that profits are significantly weighted towards the second half of its financial year, which is expected to be “another year of profit growth and development.” Markets will know more when it reports its interims on Monday (30 September).

This acquisition-hungry business now operates across 18 countries, which gives it continued growth opportunities, and Rupert Hargreaves reckons it could double your money over the next three-to-five years. DCC has an excellent track record for delivering shareholder returns, although that’s reflected in its valuation, which is currently 18.8 times forward earnings. Sometimes you have to pay for quality.

Melrose Industries

This company’s motto is “Buy, Improve, Sell”, a nice, pithy description. Melrose Industries (LSE: MRO) aims to buy good manufacturing businesses with strong fundamentals, whose performance it reckons can be improved.

That’s worked out astonishingly well for investors. They’ve seen the share price graph 350% over five years, driving its market-cap to almost £10bn, making it one of the fastest growing stocks on the entire FTSE 100.

Earlier this month, Melrose’s interims showed a 75% increase in adjusted pre-tax profit to £428m, from £244m in the first half of last year, while revenue doubled to £6bn. It still hosted a pre-tax loss, although this narrowed from £372m to £128m on a statutory basis. If that looks odd, it’s due to the nature of the business, as acquisitions and sales can lead to massive lurches in both profits and losses. Happily, the overall trajectory has been positive.

As Alan Oscroft has pointed out, you need to be patient and have long-term horizons and like your profits lumpy. Melrose also aims to reduce risk by financing its acquisitions with a low level of leverage.

The stock trades at 15.2 times forecast earnings, with a forecast yield of 2.7%. Again, this is a growth rather than an income play. Melrose looks a strong buy and hold to me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Melrose. The Motley Fool UK has recommended Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy young female stock-picker in a cafe
Investing Articles

Operating profit up 26%! Auto Trader is leading the FTSE 100 on results day

An explosive move higher from the Auto Trader share price suggests the full-year results are good, but is the stock…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

If I’d put £2,000 in Nvidia stock when ChatGPT came out, here’s what I’d have now

Our writer looks at the eye-popping gains that Nvidia stock has made in the 18 months since the release of…

Read more »

British Pennies on a Pound Note
Investing Articles

This former penny share is up 163% in a year. Could it be worth even more?

Christopher Ruane explains some of the concerns that kept him away from a penny share before its stellar rise --…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

I’m not convinced the Dr Martens share price is a bargain. Here’s why

After the bootmaker reported its full year results today, our writer explains why a Dr Martens share price in pennies…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Should I invest in the S&P 500 or FTSE 100?

Ben McPoland thinks one FTSE 100 stock might offer a compromise between high US market growth and cheap Footsie valuations.

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

How much passive income could I earn by investing £100 a month in UK shares?

With just a £100 monthly investment in UK dividend shares, I could achieve a decent passive income stream of over…

Read more »

Young Woman Drives Car With Dog in Back Seat
Investing Articles

Looking for cheap growth shares? Here’s a FTSE 250 stock to consider in June

Pets at Home shares still look dirt cheap, says Royston Wild. Here, he explains why the retailer might be one…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

The 3 big risks to Lloyds’ share price in 2024!

Is the Lloyds share price one of the FTSE 100's worst investor traps? Royston Wild thinks the bank's shares could…

Read more »